Darmstadt, Germany (ots/PRNewswire) - - Agreement provides Merck with exclusive license to cognitive remediation training programs - HAPPYneuron will be available for inclusion in Merck's MSdialog platform for use with Rebif® (interferon beta-1a) Merck, a leading science and technology company, announced today that ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
Paris (ots/PRNewswire) - Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
London (ots/PRNewswire) - Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral ...
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th ...
Montreal (ots/PRNewswire) - - JSS Medical Research, an international contract research organization active in over 20 countries acquires Bonne Santé in Poland as catalyst for European expansion JSS Medical Research Inc., an International Contract Research Organization (CRO) with offices in Canada, Latin America and Asia/Pacific, announced the acquisition of Bonne Santé, a Polish CRO, to accelerate the expansion into ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) Merck, a leading science and technology company, jointly announced with ...
Gothenburg, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Poster# PP3.09 Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) ...
Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan, in the ongoing, incremental dose cohort, phase I/II clinical trial, ISO-CC-005. In total 16 patients with stage IV colorectal ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...
ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC)
London and Washington (ots/PRNewswire) - Collaboration will focus on 16 cities where HIV is highly prevalent and will help monitor progress towards the attainment of UNAIDS 90-90-90 and zero discrimination and stigma targets ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC) today ...
Teva Pharmaceutical Industries Ltd.
Amsterdam (ots/PRNewswire) - Positive conclusion of a European DCP for approval of a tiotropium bromide-based maintenance treatment for those people living with COPD in a new inhaler (Zonda®) Teva Pharmaceutical Industries Ltd., announced today that it has received a positive conclusion of a DCP for BRALTUS® ...
Orlando, Florida (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #290 Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive[®*] (teduglutide) 5 mg powder and solvent for ...
London (ots/PRNewswire) - For medical trade media only - A white paper written by the Economist Intelligence Unit reports that improved regulatory harmonisation may support patient empowerment and self-care, and finds that the issue is not receiving enough attention - Self-care and improved access to consumer health ...
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that clinical data on Rebif® (interferon beta-1a), the company's high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis, and Cladribine Tablets, an investigational, oral, small ...
Calgary, Alberta (ots/PRNewswire) - "Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that new data was presented at the ERA-EDTA Congress in ...
Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology is pleased with the outcome of these meetings and will initiate preparations for a pivotal Phase II/III clinical trial in colorectal cancer. This presents the ...
JTI Japan Tobacco International AG
Geneva (ots/PRNewswire) - As the Annual Summit Takes Place This Week, Global Leaders Have an Opportunity to Scrutinize WHO's definition of transparency and accountability Health Ministers from 194 countries will gather this week in Geneva to set the direction for future health policy around the world. JTI - Japan Tobacco International - is calling for the Assembly to urgently address an alarming transparency and ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # Avelumab: 4009, TPS4134, TPS4135, 9036, TPS9105, 3055, TPS3106, 8503, 4514, 4516, 5533, TPS5600, TPS4580, 9508; tepotinib: 4072 - Abstracts featuring Merck compounds span a broad range of cancers, with an emphasis on those which are difficult-to-treat and represent ...
Teva Pharmaceuticals Europe BV
Amsterdam (ots/PRNewswire) - What can you do in 30 minutes? Catch up on your favourite sitcom? Burn 180 calories on an exercise bike? Clean the bathroom? Or break a Guinness World Records(TM) title? (Logo: http://photos.prnewswire.com/prnh/20160504/363641LOGO ) (Photo: http://photos.prnewswire.com/prnh/20160504/363642 ) That is what over 600 employees from Teva have done. Taking a break from their day jobs in areas such ...
Sunnyvale, California (ots/PRNewswire) - Next generation delivery system designed for increased throughput, higher reliability and ease of serviceability Accuray Incorporated (NASDAQ: ARAY) announced the company will showcase its portfolio of radiation therapy delivery systems and software solutions at the annual European Society for Therapeutic Radiology and Oncology (ESTRO) meeting being held in Turin, Italy April 29 - ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Chinese pivotal Phase III study meets its primary endpoint of increased progression-free survival in first-line treatment of patients with RAS wild-type metastatic colorectal cancer - Merck will work with relevant authorities to make ...
Montrusco Bolton Investments Inc.
Montreal (ots/PRNewswire) - Montrusco Bolton Investments (MBI) has reviewed the 2015 compensation of Concordia Healthcare Corp's executive team. Based on an ISS report and our in-house assessment, we are of the view that the total compensation of senior executives is exorbitant. MBI agrees with ISS that the lack of transparency regarding how compensation is determined, ...
London (ots/PRNewswire) - First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected ...